The itemized price lists that hospitals set for procedures have increased healthcare costs across the board. More transparency and charge standardization would stabilize costs.
Rideshare companies have been called on to help non-emergency medical transportation providers tackle one of the most complex problems in healthcare: ensuring patients show up to their scheduled doctors appointments.
Bundled payments are fraught with surprises and challenges, but adopting a value-based payment mindset can have far reaching benefits to patients, physicians and hospitals.
Lack of awareness around the right technology for preventing surgically retained items is causing providers to risk both patient safety and financial savings.
Drugmakers are fighting back against a request by U.S. senators who want HHS Secretary Tom Price to make it easier to import drugs from Canada as a strategy to combat rising drug prices.
Q&A with Geoff Martha, EVP and President of Medtronic Restorative Therapies Group, on how hospitals can improve patient outcomes and achieve success with care episodes and bundled payment models.
How an ERP cloud solution can lower costs, improve operational efficiencies and real-time analytics, and provide better tools for configurability and integration.
Pharmaceutical company Mylan is refusing to testify at a congressional hearing next week on a settlement between the company and the Justice Department over its life-saving EpiPen.
Pfizer has to give the Texas Health and Human Services Commission drug price information as part of the state's Medicaid program. But that information isn't supposed to be handed over to legislators.
To meet the changing needs of U.S. health consumers, providers are leveraging telehealth to effectively and efficiently deliver care when and where patients need it the most.
Teva Pharmaceutical Industries, the Israel-based generic drug giant, will report its financials this week amid uncertainty following the presidential election and increased competition by rival Mylan Pharmaceuticals on a generic EpiPen.
Voters rejected California's controversial drug price measure, putting an end to an expensive ballot initiative that sought to appeal to a public increasingly frustrated by high drug prices.